Literature DB >> 8645831

Pertussis in German adults.

S Schmitt-Grohé1, J D Cherry, U Heininger, M A Uberall, E Pineda, K Stehr.   

Abstract

In a large pertussis vaccine efficacy trial in Germany, vaccinees and/or their family members were seen if a cough illness of >14 days was reported. Evidence of recent Bordetella pertussis infection included a positive culture and/or polymerase chain reaction (PCR) and/or significant antibody values in agglutination and/or ELISA assay. From July 1991 through February 1994, 246 adults were evaluated and 64 had evidence of B. pertussis infection; of these, 38% had whooping, 26% had a history of previous pertussis, and 48% were the primary cases in a family. The 64 adult cases suggest an adult attack rate in this population of 133 per 100,000 population per year. Since pertussis has been endemic and epidemic in Germany during the last 2 decades, it would seem likely that few persons would escape B. pertussis infections during childhood. In this regard, none of the serological controls lacked antibody to all four B. pertussis antigens (lymphocytosis-promoting factor, filamentous hemagglutinin, pertactin, and fimbriae-2). Thus, serological evidence of past infection may not indicate protection, and the widely held belief that individuals who have had infections with B. pertussis have lifelong clinical immunity to this disease is probably wrong.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8645831     DOI: 10.1093/clinids/21.4.860

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  26 in total

1.  Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis.

Authors:  H E de Melker; F G Versteegh; M A Conyn-Van Spaendonck; L H Elvers; G A Berbers; A van Der Zee; J F Schellekens
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Seroprevalence of pertussis among Danish patients with cough of unknown etiology.

Authors:  Tine Dalby; Zitta B Harboe; Karen Angeliki Krogfelt
Journal:  Clin Vaccine Immunol       Date:  2010-10-06

3.  Impact of vaccination and birth rate on the epidemiology of pertussis: a comparative study in 64 countries.

Authors:  H Broutin; C Viboud; B T Grenfell; M A Miller; P Rohani
Journal:  Proc Biol Sci       Date:  2010-06-09       Impact factor: 5.349

4.  Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States.

Authors:  Andrew L Baughman; Kristine M Bisgard; Kathryn M Edwards; Dalya Guris; Michael D Decker; Kathy Holland; Bruce D Meade; Freyja Lynn
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

5.  Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis.

Authors:  Girish S Kirimanjeswara; Luis M Agosto; Mary J Kennett; Ottar N Bjornstad; Eric T Harvill
Journal:  J Clin Invest       Date:  2005-11-17       Impact factor: 14.808

6.  Pathogen adaptation under imperfect vaccination: implications for pertussis.

Authors:  Michiel van Boven; Frits R Mooi; Joop F P Schellekens; Hester E de Melker; Mirjam Kretzschmar
Journal:  Proc Biol Sci       Date:  2005-08-07       Impact factor: 5.349

7.  Pertussis immunization for adolescents: What are we waiting for?

Authors:  S A Halperin
Journal:  Can J Infect Dis       Date:  2001-03

8.  A comparison of pertussis rates in the Northwest Territories: Pre- and postacellular pertussis vaccine introduction in children and adolescents.

Authors:  Kami Kandola; Amy Lea; Wanda White; Maria Santos
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-09       Impact factor: 2.471

9.  The role of the acellular pertussis vaccine and the demise of 'Pertussis Pete'.

Authors:  J M Conly; B L Johnston
Journal:  Can J Infect Dis       Date:  2001-01

10.  Quantification of the adenylate cyclase toxin of Bordetella pertussis in vitro and during respiratory infection.

Authors:  Joshua C Eby; Mary C Gray; Jason M Warfel; Christopher D Paddock; Tara F Jones; Shandra R Day; James Bowden; Melinda D Poulter; Gina M Donato; Tod J Merkel; Erik L Hewlett
Journal:  Infect Immun       Date:  2013-02-19       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.